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ABSTRACT Endovascular infections caused by methicillin-resistant Staphylococcus
aureus (MRSA) are a major health care concern, especially infective endocarditis (IE).
Standard antimicrobial susceptibility testing (AST) defines most MRSA strains as “re-
sistant” to -lactams, often leading to the use of costly and/or toxic treatment regi-
mens. In this investigation, five prototype MRSA strains, representing the range of
genotypes in current clinical circulation, were studied. We identified two distinct
MRSA phenotypes upon AST using standard media, with or without sodium bicar-
bonate (NaHCO3) supplementation: one highly susceptible to the antistaphylococcal
-lactams oxacillin and cefazolin (NaHCO3 responsive) and one resistant to such
agents (NaHCO3 nonresponsive). These phenotypes accurately predicted clearance pro-
files of MRSA from target tissues in experimental MRSA IE treated with each -lactam.
Mechanistically, NaHCO3 reduced the expression of two key genes involved in the MRSA
phenotype, mecA and sarA, leading to decreased production of penicillin-binding protein
2a (that mediates methicillin resistance), in NaHCO3-responsive (but not in NaHCO3-
nonresponsive) strains. Moreover, both cefazolin and oxacillin synergistically killed
NaHCO3-responsive strains in the presence of the host defense antimicrobial peptide
(LL-37) in NaHCO3-supplemented media. These findings suggest that AST of MRSA
strains in NaHCO3-containing media may potentially identify infections caused by
NaHCO3-responsive strains that are appropriate for -lactam therapy.
KEYWORDS antimicrobial susceptibility testing, MRSA, -lactams, infective
endocarditis, penicillin-binding proteins, sodium bicarbonate
Staphylococcus aureus is a major bloodstream pathogen in both community-acquiredand nosocomially acquired scenarios and is the leading cause of infective endocar-
ditis (IE) in the industrialized world (1). Compounding the danger of S. aureus blood-
stream infections (BSIs) is the steady rise of methicillin-resistant Staphylococcus aureus
(MRSA) strains in many geographic regions in the United States (2). MRSA is a serious
infectious threat, causing more than 15,000 deaths in the United States each year (3).
MRSA have high MICs that are above Clinical and Laboratory Standards Institute
(CLSI) resistance breakpoints for most conventional -lactam antibiotics, such as oxa-
cillin, on standard antimicrobial susceptibility testing (AST) media. This finding implies
a lack of efficacy of these agents in treating MRSA infections, as confirmed in selected
experimental IE studies (4–6). Treatment options for MRSA are generally limited to
costlier and/or more toxic drugs, such as vancomycin, daptomycin, and lipoglycopep-
tides, and fifth-generation cephalosporins, such as ceftaroline (7–9). In addition, great
expense and effort have gone into development of such newer anti-MRSA drugs
(10, 11).
AST protocols for MRSA have been standardized by the CLSI and involve growth of
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bacterial samples in 2% NaCl cation-supplemented, nutrient-rich Mueller-Hinton broth
(CA-MHB) (12, 13). However, MHB does not accurately represent the host milieu, and
MICs observed in this medium are unlikely to mirror those exhibited by MRSA within
specific host microenvironments. Although research efforts have been made to effec-
tively model the host microenvironment in vitro or ex vivo (e.g., using simulated
endocardial vegetations [SEVs]) (14, 15), these models are not suitable for large-scale
AST in clinical laboratories.
Recently, several groups have attempted to improve standardized AST by altering
growth conditions to better reflect the host environment. For example, AST of intra-
cellular bacteria, such as Salmonella, in media that models the host phagolysosome can
better predict treatment outcomes in murine bacteremia models (16, 17). Growth of
bacteria in Dulbecco modified Eagle medium (DMEM) (but not in standard AST media)
can stimulate expression of virulence factors typically exhibited in vivo (18, 19). These
observations led to the discovery that AST of extracellular bacteria performed in such
cell culture medium (including DMEM and RPMI 1640) was a better predictor of in vivo
treatment outcomes than standard AST media for Acinetobacter and some staphylo-
cocci (17, 20). Of note, Dorschner et al. identified the role of physiological concentra-
tions of NaHCO3 in facilitating the in vitro killing of Escherichia coli and MRSA by host
antimicrobial peptides (AMPs) (21). The carbonate molecule was capable of altering
expression of a number of key regulatory genes in E. coli, including the homolog of the
MRSA stress response regulator, sigma factor B (sigB). Finally, our lab has recently
confirmed the key role of NaHCO3 supplementation in rendering a range of bacterial
pathogens, including MRSA, as more susceptible in vitro to multiple antibiotics, includ-
ing -lactams (17). The predictive role of this “NaHCO3-responsive” phenotype, vis-à-vis
salutary outcomes to -lactam therapy, was corroborated in a murine bacteremia
model (17).
In the present study, we focused on the activity of two -lactam agents routinely
used for treating methicillin-susceptible S. aureus (MSSA) infections against five
well-characterized prototype MRSA strains, in the presence or absence of NaHCO3-
supplemented standard media. Using this modified AST schema, we demonstrate that
NaHCO3 supplementation increased the in vitro susceptibility of selected MRSA strains
to both cefazolin and oxacillin (i.e., NaHCO3-responsive MRSA). Although these drugs
are typically not recommended for the treatment of MRSA (22), we observed that they
can be highly effective in treating such NaHCO3-responsive MRSA strains in a rabbit
model of IE. In contrast, MRSA strains that were NaHCO3 nonresponsive in vitro were
recalcitrant to such -lactam therapy in vivo.
If verified in larger MRSA screening studies, these novel findings may potentially
prompt modifications of AST for MRSA; this, in turn, could potentially guide new
treatment algorithms for selected MRSA infections with -lactam agents such as
cefazolin and antistaphylococcal penicillins. Finally, mechanistically, NaHCO3 respon-
siveness correlated with the capacity of this molecule to suppress at least two key
regulatory pathways intimately involved in the MRSA phenotype:mecA-PBP2a and sarA
(5, 23, 24).
RESULTS
Effect of NaHCO3 on -lactam susceptibility in vitro. MIC values obtained in
standard CA-MHB for the five study strains were generally within 2-fold of those
obtained in CA-MHB plus 100 mM Tris (CA-MHB-Tris; see Table S1 in the supplemental
material). MRSA strains 11/11 (USA300 genotype) and MW2 (USA400 genotype) dis-
played a substantial decrease in MICs to cefazolin and oxacillin when grown in media
containing 44 mM NaHCO3 (Table 1). Strain MRSA 11/11 also displayed a decrease in
MICs to cefazolin and oxacillin, albeit less pronounced, when exposed to a more
physiologically relevant concentration of NaHCO3 (25 mM). In contrast, -lactam MICs
for three other prototype MRSA strains, COL (USA100 genotype), BMC1001 (USA500
genotype), and 300-111 (CC8, spa type 4, Iberian clone) were unaffected by exposure
to NaHCO3 at either concentration (Table 1). Based on these two distinct phenotypes,
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we termed the two strains above, whose -lactam MICs were substantially reduced by
NaHCO3, “responsive,” while we termed the other three strains, whose -lactam MICs
were unaffected by NaHCO3, “nonresponsive.”
In addition, several recent investigations have promoted the use of the tissue culture
medium, RPMI 1640, as a more physiologic, host-mimicking media and a better
predictor of in vivo susceptibility to various antimicrobials than standard growth media,
especially for Gram-negative bacteria (20, 25). As opposed to our NaHCO3 assays, we
found that MICs to both -lactams were decreased in RPMI 1640 for all five of our study
strains, although the effect was somewhat less substantive for strain COL (Table 1).
To evaluate whether NaHCO3 sensitization of MRSA to -lactams was merely a
“weak acid” effect, we investigated the impact of salicylic acid exposure on -lactam
MICs among four of our study strains. Exposure of these MRSA strains to 25 and
50 g/ml salicylic acid, concentrations that are physiologically achievable during aspirin
therapy (26), had no effect on the -lactam MICs in any strain tested (Table S1). These
data are in accord with those of Farha et al. using two other weak acid molecules,
acetate and borate (27). Taken together, this finding indicates that -lactam resensiti-
zation of some MRSA in the presence of NaHCO3 is not the result of a generalized weak
acid effect.
To further quantify the effect of NaHCO3 on MRSA -lactam susceptibility profiles, a
time-kill assay was conducted using log-phase responsive MRSA 11/11 or nonrespon-
sive COL cells. As predicted by the MIC data, MRSA 11/11 displayed significantly greater
killing when exposed to cefazolin and oxacillin in NaHCO3-containing media compared
to NaHCO3-free media (Fig. 1A). After a 24 h of incubation, a4-log10 CFU/ml reduction
in counts was observed for MRSA 11/11 exposed to 8 g/ml cefazolin or 15 g/ml
oxacillin in NaHCO3-containing versus NaHCO3-free media. These latter -lactam con-
TABLE 1MICs of -lactam antibiotics against methicillin-resistant S. aureus grown in media with and without NaHCO3a
Treatment
Cefazolin MIC (g/ml) Oxacillin MIC (g/ml)
MRSA 11/11 MW2 COL BMC1001 300-111 MRSA 11/11 MW2 COL BMC1001 300-111
CA-MHB-Tris 16 8 256 256 64 32 64 512 256 16
CA-MHB-Tris  25 mM NaHCO3 4 8 512 256 32 4 32 512 256 16
CA-MHB-Tris  44 mM NaHCO3 0.5 1 256 256 32 0.5 2 512 256 32
RPMI 1640 10% LB medium 1 2 16 2 2 1 1 64 16 4
aMIC values obtained in CA-MHB-Tris for strains MRSA 11/11, MW2, COL, and BMC1001 were within 2-fold of those obtained in standard CA-MHB (see Table S1 in the
supplemental material). The MIC values for 300-111 in CA-MHB were 16 and 8 g/ml for cefazolin and oxacillin, respectively.
FIG 1 Time-kill analysis of log-phase cells grown in media with or without NaHCO3. (A) MRSA 11/11; (B)
COL. Growth in CA-MHB-Tris (closed symbols) or in CA-MHB-Tris plus 44 mM NaHCO3 (open symbols)
with no drug (circles), 8 g/ml cefazolin (triangles), 32 g/ml cefazolin (diamonds), or 15 g/ml oxacillin
(squares) is indicated. The data are means of two independent runs performed in triplicate for each
condition  the SD. Statistical comparisons were made using a Kruskal-Wallis single-factor ANOVA and
the post hoc pairwise Mann-Whitney U test. Asterisks represent comparisons (**, P 0.01) at the 24-h
time point of MRSA 11/11 exposed to 8 g/ml cefazolin in CA-MHB-Tris versus CA-MHB-Tris plus 44 mM
NaHCO3 and 15 g/ml oxacillin in CA-MHB-Tris plus 2% NaCl versus CA-MHB-Tris plus 2% NaCl plus
44 mM NaHCO3.
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centrations represent sublethal concentrations as determined in multiple pilot time-kill
studies carried out in NaHCO3-free media. In contrast, strain COL displayed a minimal
reduction in counts when grown in NaHCO3-containing versus NaHCO3-free media
under all testing conditions (Fig. 1B). Similar differential time-kill results were obtained
for the NaHCO3-responsive strain MW2 and the NaHCO3-nonresponsive strain BMC1001
(Fig. S1). Interestingly, the nonresponsive strain 300-111, which has a relatively low
baseline level of resistance to cefazolin and oxacillin, displayed an intermediate level of
killing when exposed to 8 g/ml cefazolin or 15 g/ml oxacillin in NaHCO3-containing
versus NaHCO3-free media (Fig. S1).
Supplementation with 44 mM NaHCO3 had only a modest effect on 24-h growth
kinetics for the five study strains (Fig. S2). With the exception of COL and 300-111,
stationary-phase cell counts at 24 h were not significantly different between media with
versus without 44 mM NaHCO3 for any strain tested.
Population analyses in NaHCO3-containing media. Population analysis profiles
(PAPs) are a standard quantitative in vitro assessment of the proportions of antibiotic-
resistant subpopulations within a given strain versus specific antibiotics (28). MRSA
strains contain a variable proportion of highly -lactam-resistant subpopulations. For
example, homogeneously resistant (homoresistant) strains usually contain a high per-
centage (e.g., 10%) of such subpopulations, whereas heterogeneously resistant (het-
eroresistant) strains generally contain a lower percentage (e.g., 0.01%) of resistant
subpopulations.
To determine the effect of NaHCO3 on -lactam-resistant subpopulations, PAPs for
cefazolin were determined for our five prototype MRSA strains in NaHCO3-containing
versus NaHCO3-free agar. NaHCO3-responsive strains MRSA 11/11 and MW2 displayed
heteroresistant PAP phenotypes on NaHCO3-free agar, whereas NaHCO3-nonresponsive
strains COL, BMC1001, and 300-111 each displayed a more homoresistant PAP pheno-
type (Fig. 2A). To better characterize -lactam heteroresistant versus homoresistant
phenotypes, using COL as our benchmark homoresistant strain, we calculated the area
under the PAP curve (AUC) ratios for MRSA 11/11, MW2, BMC1001, and 300-111 with
respect to the COL AUC. AUC ratios of NaHCO3-responsive strains were significantly
lower in the presence of NaHCO3 (compare Fig. 2A to B). Although NaHCO3 did have
a slight repressive effect on the resistant subpopulation of 300-111, the AUC for this
strain in 44 mM NaHCO3 was significantly greater than both MRSA 11/11 and MW2.
NaHCO3 had no effect on the AUC ratio of BMC1001 or the proportion of highly
resistant COL or BMC1001 cells (Fig. 2B). Exposure to oxacillin, with or without NaHCO3,
yielded similar results to cefazolin, although the magnitude of suppression of the highly
resistant subpopulations of the two NaHCO3-responsive strains (MRSA 11/11 and MW2)
was less than that seen with cefazolin, and the differences were not statistically
significant (data not shown).
Rabbit IE treatment outcomes with -lactams. To verify the in vivo translatability
of the NaHCO3 responsivity phenotypes determined in vitro, a rabbit model of aortic
valve IE, treated with the two study -lactams, was used. The -lactam treatment
regimens were based on (i) published protocols for experimental IE therapy that are
capable of clearing MSSA strains from target tissues (5, 29), (ii) human-mimicking
pharmacokinetic profiles (5, 29) (Table S2), and (iii) our own pilot treatment outcome
studies of experimental MSSA IE with these regimens (Fig. S4). As predicted by in vitro
MICs determined in NaHCO3-containing media, both NaHCO3-responsive strains were
highly susceptible to -lactam therapy in vivo to levels not dissimilar from that seen
with the MSSA control strain ATCC 25923 (Fig. 3A; see also Fig. S4 in the supplemental
material). Thus, significant clearance of MRSA 11/11 and MW2 was observed in all target
tissues sampled after 4 days of either cefazolin or oxacillin therapy. Of note, sterilization
of multiple target tissues was seen in 70% of organ cultures from animals infected
with the two NaHCO3-responsive when treated with cefazolin; in contrast, oxacillin
therapy did not sterilize any target tissues despite significant reductions in MRSA
counts in IE caused by these latter strains (data not shown). In contrast, -lactam
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therapy was ineffective in reducing bacterial counts in the target tissues of rabbits
infected with two NaHCO3-nonresponsive strains, COL or BMC1001 (Fig. 3B). The in vitro
NaHCO3-nonresponsive strain, 300-111, displayed a significant reduction in bacterial
counts in all target tissues following cefazolin and oxacillin treatment; however, the
magnitude of killing was significantly less than that observed in either NaHCO3-
responsive strain (Fig. 3B). Interestingly, the MICs determined in CA-MHB-Tris contain-
ing 44 mM NaHCO3 were better predictors of treatment outcomes for all five strains
than were the MICs determined in RPMI 1640, based roughly on previously established
2014 CLSI breakpoints (cefazolin breakpoints are no longer employed in the current
2018 CLSI guidelines [13, 30]: S 8 g/ml, I 16 g/ml, R 32 g/ml) and current
oxacillin breakpoints (S 2 g/ml, R 4 g/ml [31]).
It was important to ensure that -lactam therapy in experimental IE caused by the
NaHCO3-responsive strains did not select for highly -lactam-resistant subpopulations
within target tissues after -lactam therapy. Thus, at the time of sacrifice, homogenates
from these organs were parallel plated onto tryptic soy agar (TSA) containing 64 g/ml
of either cefazolin or oxacillin in animals treated with these respective agents. No such
high-level -lactam-resistant colonies were detected for either MRSA 11/11-infected or
MW2-infected animals after therapy with either of the two -lactam agents (data not
shown).
To investigate whether exposure to NaHCO3 itself might influence the tissue bur-
dens of NaHCO3-responsive strains during induction of infection, in a separate study,
MRSA 11/11 was grown overnight in CA-MHB-Tris containing 25 or 44 mM NaHCO3
prior to infection of aortic valve-catheterized animals. At 24 h postinfection, there were
no significant differences in target tissue MRSA counts between rabbits infected with
FIG 2 Population analysis of cells grown in media with or without NaHCO3. (A) Mueller-Hinton agar (MHA)
supplemented with Tris (closed symbols); (B) MHA supplemented with Tris and 44 mM NaHCO3 (open symbols).
Data for strains MRSA 11/11 (solid black line), MW2 (dashed black line), 300-111 (dotted gray line), COL (solid gray
line), and BMC1001 (dashed gray line) are shown. CFZ, cefazolin. Area under the curve (AUC) ratios were compared
to COL as a homoresistant reference strain. The data are means of two independent runs performed in triplicate
for each condition the SD. Statistical comparisons were made using a Kruskal-Wallis single-factor ANOVA and the
post hoc pairwise Mann-Whitney U test. MRSA 11/11, MW2, and 300-111 AUC in media containing 44 mM NaHCO3
were significantly reduced compared to strains in media without NaHCO3 (*, P 0.05; **, P 0.01; ****, P 0.0001);
the AUC ratio of 300-111 in media containing 44 mM NaHCO3 is significantly greater than that of MRSA 11/11 and
MW2 (*, P  0.05).
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MRSA 11/11 grown in NaHCO3-free CA-MHB-Tris versus 25 or 44 mM NaHCO3-
containing CA-MHB-Tris (Fig. S3B). This confirmed that bicarbonate preexposure itself
did not hinder the induction and early progression phases of infection in experimental
IE caused by NaHCO3-responsive strains.
NaHCO3 levels in experimental IE. To put our in vivo outcomes in experimental IE
into perspective, we measured [HCO3–] levels in both infected and uninfected rabbits.
Quantification of [HCO3–] concentrations in the blood of animals with IE versus unin-
fected controls revealed that blood [HCO3–] levels remained relatively constant in the
range of 20 to 25 mM (Fig. S3C). The fact that the maximal in vitro impact of NaHCO3
supplementation of standard media was seen at 44 mM versus 25 mM suggested that
other factors are likely in play in vivo which contribute to NaHCO3 responsivity in
experimental IE (e.g., host immune molecules and/or cells).
LL-37 synergy with -lactams in the presence of physiological concentrations
of NaHCO3. We hypothesized that the high-level killing exhibited by -lactams in vivo
against the two NaHCO3-responsive strains in the presence of physiologic concentra-
tions of NaHCO3 (ca. 20 to 25 mM) may be due to a synergistic effect between
-lactams and host immune factors, particularly host defense peptides. To further
FIG 3 Treatment outcomes of rabbits with infective endocarditis treated with -lactams. (A) NaHCO3-
responsive strains; (B) NaHCO3-nonresponsive strains. All rabbits were treated with 100 mg/kg of
cefazolin (CFZ) or oxacillin (OX), t.i.d., intramuscularly, for 4 days. Data for strains MRSA 11/11 (control,
n 6; CFZ, n 8; OX, n 6), MW2 (control, n 7; CFZ, n 6; OX, n 7), COL (control, n 6; CFZ, n 7;
OX, n 6), BMC1001 (control, n 6; CFZ, n 7; OX, n 7), and 300-111 (control, n 10; CFZ, n 4; OX,
n 6) are shown. The data presented indicate the mean tissue CFU/g for each treatment group  the
SD. Statistical comparisons were made using a Kruskal-Wallis single-factor ANOVA and the post hoc
pairwise Mann-Whitney U test (**, P 0.01). Strain 300-111 had significantly greater cell counts in all
target tissues following cefazolin and oxacillin therapy compared to both MRSA 11/11 and MW2
(*, P 0.05).
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investigate this, we performed a cell survival assay utilizing sublethal concentrations of
the human cathelicidin, LL-37, in combination with cefazolin or oxacillin, in a minimal
medium containing 25 mM NaHCO3. Strains were exposed to LL-37 and the -lactams
alone or in combination in the presence of this physiological concentration of NaHCO3.
When exposed to a combination of LL-37 and either cefazolin or oxacillin, both
NaHCO3-responsive strains displayed significantly lower MRSA survivals compared to
either -lactam agent alone (Fig. 4A and B). In contrast, the NaHCO3-nonresponsive
strain, COL, did not display synergistic killing when exposed to a combination of LL-37
plus either cefazolin or oxacillin (Fig. 4C), consistent with the results seen in the IE
model. These data indicate that, although higher concentrations of NaHCO3 (44 mM)
are required in vitro to disclose “responsiveness” among MRSA strains, host defense
and/or other serum factors may foster such responsivity in vivo in combination with
more physiologic NaHCO3 levels (ca. 20 to 25 mM).
FIG 4 LL-37 synergy with -lactams in media containing 25 mM NaHCO3. (A) MRSA 11/11 (NaHCO3
responder); (B) MW2 (NaHCO3 responder); (C) COL (NaHCO3 nonresponder). CFZ, cefazolin; OX, oxacillin.
Bars: no drug, hatched; LL-37 only, white; CFZ or OX, black; CFZ or OX plus LL-37, gray. MRSA 11/11 was
exposed to 2.5 g/ml LL-37 and 0.03125 g/ml CFZ or OX. MW2 and COL were exposed to 5 g/ml LL-37
and 0.0625 g/ml CFZ or OX. The percent survival was calculated after 4 h of exposure to antimicrobials
in NaHCO3-free DMEM supplemented with 25 mM NaHCO3. The data are means of three independent
runs performed in triplicate for each condition  the SD. Statistical comparisons were made using a
Kruskal-Wallis single-factor ANOVA and the post hoc pairwise Mann-Whitney U test (**, P 0.01; ***,
P 0.001).
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Mechanisms of NaHCO3-mediated -lactam resensitization of MRSA: mecA and
sarA expression. To understand the potential genetic basis for altered -lactam
susceptibility in selected MRSA strains in NaHCO3-containing media, we investigated
the influence of NaHCO3 on mecA and sarA gene expression. The mecA locus encodes
penicillin-binding protein 2a (PBP2a) that confers -lactam resistance in MRSA strains
(24). In addition, recent studies have demonstrated that the global virulence gene
regulator, sarA, can also modulate -lactam resistance via both mecA-dependent and
mecA-independent mechanisms (23). To investigate the influence of NaHCO3 exposure
on mecA and sarA gene expression, RNA was extracted from cells grown in media with
and without NaHCO3 in the absence or presence of 1/2 MIC of oxacillin (to maximally
induce mecA expression). The quantitative real-time PCR (qRT-PCR) analyses revealed
that mecA and sarA gene expression were each significantly repressed in the two
NaHCO3-responsive strains under both these mecA-noninducing and -inducing condi-
tions (Fig. 5A and B). In contrast, mecA gene expression was not repressible in any
NaHCO3-nonresponsive strain (Fig. 5A and B). The expression of sarA was only slightly
repressed in COL in NaHCO3-supplemented media with oxacillin induction but was
nonrepressible in media without oxacillin induction (Fig. 5A and B). The expression of
sarA was also not repressible in the other NaHCO3-nonresponsive strains, BMC1001 and
300-111 (Fig. 5A and B).
To phenotypically verify that the mecA repression observed in NaHCO3-responsive
strains correlated with diminished PBP2a protein production, a macroagglutination
PBP2a production assay was utilized. A clear reduction in PBP2a agglutination was
observed in both NaHCO3-responsive strains after growth in NaHCO3-containing media
(Table 2; see Fig. S3 in the supplemental material), consistent with the reduced
expression of mecA. The NaHCO3-nonresponsive strains, COL and BMC1001, displayed
high levels of agglutination in media with and without NaHCO3 exposures (Table 2; see
Fig. S3 in the supplemental material). Although mecA gene expression was not repres-
sible in strain 300-111 in the presence NaHCO3, the level of observable PBP2a agglu-
tination was slightly diminished in media containing NaHCO3.
Lipase production is one of the signature phenotypes normally repressed by the
global regulator sarA (32, 33). To phenotypically confirm the blunting of sarA gene
expression by NaHCO3 exposures seen in NaHCO3-responsive versus -nonresponsive
strains, a tributyrin clearance assay was used to measure lipase production. As pre-
dicted by NaHCO3 repression of sarA gene expression, NaHCO3-responsive strains had
significantly higher levels of lipase activity when exposed to NaHCO3 (Fig. 5C). In
contrast, lipase production in NaHCO3-nonresponsive strains was not affected by the
presence of NaHCO3 (Fig. 5C).
DISCUSSION
Several studies have demonstrated the importance of NaHCO3, the body’s primary
biological buffer, in altering susceptibility of S. aureus to various antibiotics, including
-lactams, as well as to the prototypical host defense peptide, LL-37 (17, 21, 27). Here,
we show the ability of NaHCO3 to increase susceptibility in selected MRSA strains to two
conventional -lactam agents commonly used to treat MSSA infections. This raises the
intriguing possibility of treating MRSA infections with such -lactam agents, a concept
not currently endorsed by any therapeutic guidelines for MRSA (22). Since such
-lactams are relatively inexpensive and exhibit infrequent serious side effects (34), our
findings are of potential clinical relevance. The results show that certain MRSA strains
found to be -lactam susceptible in vitro by AST with NaHCO3 supplementation can be
effectively treated by -lactam therapy in a prototypical model of endovascular infec-
tions, experimental IE.
In vitro, NaHCO3-responsive MRSA strains have a typical signature. They are hetero-
resistant on PAPs and have relatively low MICs within the MRSA range to conventional
-lactams (i.e., to cefazolin and oxacillin). Phenotypically, compared to NaHCO3-
nonresponsive MRSA strains, such NaHCO3-responsive MRSA strains are killed signifi-
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cantly better in vitro by these -lactams in the presence versus absence of NaHCO3, and
NaHCO3 substantially represses the growth of their resistant subpopulations.
Importantly, not all strains with relatively low intrinsic -lactam MICs display the
NaHCO3-responsive phenotype, as demonstrated by strain 300-111. Despite displaying
nearly identical basal -lactam MICs to MRSA 11/11 in standard media, this “interme-
diate” NaHCO3-nonresponsive strain was incompletely cleared from target tissues in
experimental IE following cefazolin and oxacillin treatment. These outcomes under-
FIG 5 mecA and sarA expression in NaHCO3-responsive and NaHCO3-nonresponsive strains. (A) qRT-PCR analysis of mecA and sarA gene
expression in stationary-phase cells grown in CA-MHB-Tris with or without NaHCO3. (B) qRT-PCR analysis ofmecA and sarA gene expression
in stationary-phase cells grown in CA-MHB-Tris plus 2% NaCl with or without NaHCO3 with 1/2 MIC of oxacillin. Gene expression levels
are normalized to the housekeeping gene gyrB. Gene expression values are normalized to CA-MHB-Tris for each strain. All data are derived
from two independent biological replicates, tested in triplicate on two separate occasions. (B) Lipase production analysis in NaHCO3-
responsive and -nonresponsive strains grown in media with or without NaHCO3. Values normalized to CA-MHB-Tris for each strain. The
data are means of two independent runs performed in triplicate for each condition  the SD. Statistical comparisons were made using
a Kruskal-Wallis single-factor ANOVA and the post hoc pairwise Mann-Whitney U test (*, P 0.05; **, P 0.01; ****, P 0.0001).
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score the concept that the resistant subpopulations of such low-MIC, but NaHCO3-
nonresponsive strains cannot be simply eliminated by achieving supra-MIC -lactam
serum levels in such infections. More such “intermediate” strains need to be studied in
the IE model to verify this concept.
In our investigations, AST was performed at both 44 mM NaHCO3, a concentration
present in certain cell culture media (e.g., DMEM), as well as at 25 mM NaHCO3, a
physiologically relevant concentration for humans and rabbits (35). Although we saw
highly effective -lactam-mediated killing of our “responsive” strains in vivo, we saw
only a modest impact at physiologically relevant concentrations of 25 mM NaHCO3 in
vitro. These results suggested that other factors previously implicated in endovascular
pathogenesis, such as host defense peptides (e.g., LL-37 or -defensin, hNP-1 [36–38]),
might synergize with -lactams at physiological NaHCO3 concentrations to yield in vivo
killing mirroring those observed in vitro at 44 mM NaHCO3. Of note, data, at least for
LL-37, supported this notion. We recognize that other innate host immune factors (e.g.,
neutrophils, serum complement, other host peptides, antistaphylococcal antibodies,
etc.) may also contribute to enhanced bacterial killing by -lactams in vivo in the
presence of physiological concentrations of NaHCO3.
In terms of how physiological concentrations of NaHCO3 might impact MRSA to alter its
intrinsic -lactam susceptibility profiles, Farha et al. (27) proposed that this molecule was
simply acting through its capacity to collapse the proton motive force (PMF; PMF  Δ 
ΔpH). Thus, [HCO3–], via Le Chatelier’s principle, would drive the reaction, H  [HCO3–]
 H2OCO2 to consume protons and collapse PMF by mitigating the ΔpH. In their
study, these researchers found that anMSSA strain becamemore resistant to oxacillin in the
presence of NaHCO3 (27) and attributed their observations to globally decreased cellular
respiration and growth rates. Since -lactams are more effective against rapidly dividing
cells, these authors postulated the mechanism to be based in an overall impact of reduced
respiratory energy production to fuel growth in the presence of PMF-modifying concen-
trations of NaHCO3. In contradistinction, our study observed essentially the opposite result
in MRSA, i.e., that certain MRSA strains become highly susceptible to -lactams in the
presence of NaHCO3, indicating that additional changes to MRSA-defining gene expression
patterns may overcome any inhibitory effect of NaHCO3 on global cell metabolism to
render such strains as -lactam susceptible.
The -lactam treatment of rabbits infected with in vitro NaHCO3-responsive strains
was highly effective in clearing infection in all target organs assessed. It was hypoth-
esized that a decrease in overall virulence stimulated by growth in a NaHCO3-
containing microenvironment might be part of the explanation for increased suscep-
tibility to -lactam antibiotics under these conditions. However, overnight growth of
the NaHCO3-responsive strain, MRSA 11/11, in the presence of 25 or 44 mM NaHCO3
prior to infection had no effect on the strain’s ability to induce or propagate experi-
mental IE.
Intriguingly, our in vitro MIC data obtained in CA-MHB containing 44 mM NaHCO3
was a better predictor of in vivo outcomes than the tissue culture medium RPMI 1640.
Although use of the latter medium for AST is gaining some traction as a “host
mimicking milieu” (especially for Gram-negative pathogens [20, 25, 39]), we found that
it falsely predicted the efficacy of oxacillin and cefazolin for the in vivo treatment of
TABLE 2 PBP2a agglutination of NaHCO3-responsive and -nonresponsive strains grown in
media with or without 44 mM NaHCO3
Strain
PBP2a agglutination levela
CA-MHB-Tris CA-MHB-Tris, 44 mM NaHCO3
MRSA 11/11  –
MW2  –
COL  
BMC1001  
300-111  
aInterpretation of agglutination intensity: , high; , moderate; , low; and –, none.
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some study MRSA strains, (e.g., BMC1001). Further head-to-head screening in both
media, using larger MRSA strain collections, will be required to fully identify which
medium is the best predictor of -lactam efficacy in vivo against MRSA.
Gene expression analyses revealed thatmecA and sarA were highly repressed in vitro
in NaHCO3-responsive versus NaHCO3-nonresponsive strains. Repression of the mecA
gene was, in turn, found to directly correspond to a decrease in PBP2a protein
expression. It is unclear, however, whether NaHCO3 has a direct impact on mecA
expression, or whether altered mecA gene expression is mediated through repression
of sarA or other global regulons. Recent studies have shown that deletion of sarA and
sigB can reduce mecA expression (23); therefore, NaHCO3 may be altering mecA
expression directly and/or through one or both of these global regulatory pathways. In
addition, we observed that the mecA and sarA expression levels were reduced by
NaHCO3 exposures in both the presence and the absence of oxacillin induction (Fig. 5A
and B). This raises an intriguing dual-mechanism notion that NaHCO3 can directly effect
the basal expression of these genes, as well as interfere with mecA induction by
-lactams, such as oxacillin.
As discussed above, Dorschner et al. determined that NaHCO3 had a significant
repressive impact on expression of the E. coli homologue of the key S. aureus stress-
response regulon, sigB (21). This locus is known to regulate pigment production in S.
aureus (40); thus, factors that repress sigB expression ultimately reduce carotenoid
production, altering membrane fluidity (41). Carotenoid is critical for oligomerization
and proper insertion of PBP2a into the cell membrane (42). NaHCO3’s potentially
repressive impact on the sigB regulatory axis could thus result in a decrease in
carotenoid production. This event, combined with decreased PBP2a expression in
NaHCO3-responsive strains, could yield MRSA cells that are phenotypically “mecA
defective.” In this regard, pilot studies in our laboratory have confirmed that in vitro
NaHCO3 exposures in both “responsive” and “nonresponsive” MRSA can repress sigB
expression, as well as carotenoid production (data not shown). Thus, bicarbonate
repression of the sigB regulatory axis does not appear to play a principal role in
-lactam resensitization by bicarbonate in MRSA.
Although we have identified at least two genetic targets of NaHCO3 that may
influence MRSA resistance to -lactams, it is highly likely that NaHCO3 has pleotropic
effects on multiple gene expression profiles which may contribute to -lactam suscep-
tibility in NaHCO3-responsive strains. Furthermore, different pathways may be activated
or repressed in individual “responsive” and “nonresponsive” strains, resulting in multi-
ple “genetic types” of NaHCO3 responsiveness. For example, wall teichoic acid (WTA)
forms a scaffold for PBP2a maturation, allowing its insertion into the cell membrane
(43). Deletion of genes involved in WTA synthesis can render MRSA strains more
susceptible to -lactams (43, 44), indicating that this may be another potential site of
NaHCO3 action on gene expression. The modest decrease in PBP2a expression in strain
300-111, despite mecA expression being nonrepressible by NaHCO3 in this strain,
highlights the latter point. Thus, NaHCO3 may be affecting multiple pathways in this
nonresponsive strain, causing an increase in mecA gene expression but a slight overall
decrease in membrane insertion of mature PBP2a.
Another potential “checkpoint” for NaHCO3 is PBP4, a protein involved in the
generation of highly cross-linked peptidoglycan. Although this PBP is normally dispens-
able in MSSA (45, 46), MRSA strains require its activity for proper peptidoglycan
cross-linking (47), without which it is dependent on the -lactam-susceptible PBP2 for
peptidoglycan synthesis. Interestingly, inhibition of PBP4 activity has been shown to
diminish cell wall cross-linking in -lactam heteroresistant MRSA strains but had no
effect on cross-linking in homoresistant strains (48). Currently, little is known about the
regulation of PBP4 expression (49); however, further investigations into the effect of
NaHCO3 on PBP4 protein production may offer additional insights into mechanisms
underlying NaHCO3-responsive versus NaHCO3-nonresponsive phenotypes.
Other potential genes that might be involved in the “bicarbonate effect” in MRSA
include prsA, vraSR, mprF, and graSR (50–57). Each of these genes has been implicated
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in a phenomenon somewhat akin to NaHCO3/-lactam responsivity called the “seesaw”
effect, in which MRSA cells that evolve daptomycin resistance become resensitized to
-lactams (50–53). Many of these genetic perturbation possibilities are under active
investigation in our labs using whole-genome sequencing and RNA sequencing anal-
yses.
One of the major limitations of our study is the fact that only five MRSA strains were
investigated. We are currently screening a large collection of well-characterized clinical
MRSA strains which represent the broad range of clonal complex, agr, SCCmec, and spa
types in current worldwide circulation for their NaHCO3-responsive profiles in vitro.
Subsets of these strains will then be subjected to the same in vivo testing in the IE
model as in the current work to further verify the linkage between in vitro NaHCO3
responsivity and effective -lactam therapy in vivo.
A key in vivo finding in the present study was that, in NaHCO3-responsive MRSA IE,
neither treatment with oxacillin nor treatment with cefazolin selected for the emer-
gence of high-level (MICs  64 g/ml) -lactam-resistant subpopulations within car-
diac vegetations. It should be emphasized, however, that one additional limitation of
the present investigation was that rabbit vegetations are considerably smaller than
those of humans with IE (2 to 3 mm in diameter [corresponding to a weight of 50
to 100 mg] versus 1 cm in diameter [corresponding to 500 to 1,000 mg], respec-
tively) (50–52). Therefore, if bacterial densities observed in the rabbit IE model (which
can reach 108 to 109 CFU/gm) are similar to those in humans, then the total bacterial
burden in human vegetations would be at least 10 times higher than in the rabbit IE
model. This would correspondingly increase the chance that highly resistant subpopu-
lations might well emerge during -lactam therapy in human IE. This metric will need
to be carefully monitored in any future clinical trials. Once a reliable and facile method
for identifying potentially -lactam-responsive MRSA strains has been established and
verified, large-scale clinical trials to evaluate the effectiveness of -lactam therapy for
treating selected MRSA infections in human patients would be warranted.
MATERIALS AND METHODS
Bacterial strains and media. The methicillin-resistant Staphylococcus aureus (MRSA) strains used in
this study were all initially derived from patients with clinical infections: MRSA 11/11 (USA300), MW2
(USA400), COL (USA100), BMC1001 (USA500), and 300-111 (CC8, spa type 4, Iberian clone) (53–58). These
prototypical strains encompass the range of clonal complex, agr, and SCCmec genotypes that are in
current worldwide clinical circulation. In addition, several of these strains have been previously used in
experimental studies of virulence, pathogenesis and antimicrobial responsiveness (MW2, COL, and MRSA
11/11) (5, 23, 56, 59). In experimental IE studies, we also included the well-known MSSA strain, ATCC
25923, as a control.
MRSA and MSSA strains were stored at –80°C until thawed for use. They were isolated on tryptic soy
agar (TSA) and incubated at 37°C in ambient air. Bacteria were grown for most experiments, including
AST, overnight in cation-adjusted Mueller-Hinton broth (CA-MHB; Difco) with the addition of 100 mM Tris
(hydroxymethyl-aminomethane) to maintain pH at 7.3 0.1 throughout all AST testing (Fisher Scien-
tific). In parallel studies, CA-MHB-Tris was supplemented with either 25 or 44 mM NaHCO3; these NaHCO3
concentrations represent physiologic bloodstream concentrations, and those found in DMEM, respec-
tively. In parallel control assays, AST testing was also performed in the tissue culture medium, Roswell
Park Memorial Institute (RPMI) 1640 (Fisher Scientific) supplemented with 10% Luria-Bertani (LB) broth.
All media were supplemented with 2% NaCl when assays were performed in which MRSA cells were
exposed to oxacillin.
MIC assays. The MICs of cefazolin and oxacillin were determined according to the Clinical and
Laboratory Standards Institute (CLSI) guidelines by broth microdilution (12, 13). MRSA were grown
overnight in specified media and diluted into the same media containing 2-fold serial dilutions of
antibiotics. We added 2% NaCl to all media when performing oxacillin MICs. All MIC values are the mode
of at least six independent determinations.
For MIC determinations performed in the presence or absence of salicylic acid, we used CA-MHB plus
100 mM Tris (CA-MHB-Tris) with or without 25 or 50 g/ml salicylic acid.
Time-kill assays. Cells were grown overnight in specified testing media and diluted to 5 105
CFU/ml in 200 l of same media on a 96-well plate (flat bottom; tissue culture-treated). Based on pilot
experiments, cells were incubated at 37°C for 3 h to enter log phase and then diluted to 5 105 CFU/ml
in 200 l of the same media, with or without antibiotic, in a 96-well flat-bottom plate. Plates were then
incubated at 37°C for 24 h. Surviving cells were quantified at 0, 2, 4, 8, and 24 h of incubation, and data
are expressed as the log10 CFU/ml. A bactericidal effect was defined as a3-log10 CFU/ml decline in
counts at 24 h versus the count at 0 h.
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Population analysis profiles. The PAP protocol was modified from published guidelines (60–63). In
brief, agar plates were prepared with Mueller-Hinton Agar (MHA) supplemented with 100 mM Tris, 2%
NaCl, and 44 mM NaHCO3 (where indicated) at pH 7.3 0.1, containing 2-fold serial dilutions of
cefazolin or oxacillin at concentrations ranging from 0.0625 to 1024 g/ml. Bacterial cells were grown
overnight in broth testing medium and diluted to 1 109 CFU/ml in phosphate-buffered saline (PBS).
Ten-fold serial dilutions were performed in PBS, and 10 l of each dilution was plated onto the MHA
plates. After 48 h of incubation at 30°C, plates were enumerated for viable cells at each drug concen-
tration. The area under a population analysis profile (PAP) curve (AUC) was calculated by linear
approximation.
Synergy of -lactams with host defense peptides. For studies of -lactam synergy with host
defense peptides, a prototypical host defense peptide, LL-37, was used. This cathelicidin peptide is
commonly found in large amounts in human epithelial cells, as well as in neutrophils (64, 65), and has
been documented to play an important role in innate immunity (66–68). Highly purified LL-37 was
purchased commercially from Peptides International (Lexington, KY).
MRSA strains were grown overnight in NaHCO3-free DMEM (Gibco) supplemented with 25 mM
NaHCO3 and diluted into the same medium supplemented with 150 mM NaCl. Diluted cells were
incubated for 3 h at 37°C to enter log-phase growth. Log-phase cells were then diluted to 1 103 CFU/ml
with LL-37, cefazolin, and oxacillin, alone or in combination; this inoculum has been used as a standard
in our prior killing assays with host defense peptides (69). The final concentrations of the antimicrobials
were as follows: 2.5 g/ml LL-37 (MRSA 11/11), 5 g/ml LL-37 (MW2 and COL), 0.03125 g/ml cefazolin
and oxacillin (MRSA 11/11), and 0.0625 g/ml cefazolin and oxacillin (MW2 and COL). These antibiotic
concentrations were determined after extensive pilot studies to represent individual drug levels that did
not cause 50% killing of this starting MRSA inoculum. Surviving cells were quantified after 4 h of
incubation with antimicrobials at 37°C, and the percent survival was calculated at this time point as
follows: (CFU with antimicrobial/CFU with no antimicrobial)  100.
Isolation of RNA and quantitative real-time PCR analyses. To quantify expression of two key
genes involved in the MRSA phenotype (mecA and sarA), total RNA was isolated from the study strains
following overnight growth in media with or without NaHCO3 supplementation using an RNeasy kit
(Qiagen, Valencia, CA) (59). Cells were grown overnight in specified media (CA-MHB-Tris  44 mM
NaHCO3) and then diluted 1:100 into the same media and, followed by incubation at 37°C overnight. To
quantify the combined effect of oxacillin stimulation and NaHCO3 exposure on gene expression, cells
were grown as specified, but diluted into media containing 1/2 MIC of oxacillin (with 2% NaCl). qRT-PCR
was performed using primers for mecA, sarA, and gyrB as previously described (59, 70, 71). gyrB was used
as a housekeeping gene to normalize transcript quantifications. Relative quantification was calculated
using the ΔΔCT method. All qRT-PCR gene expression data were determined from two separate biological
replicates for each condition, tested in triplicate. The data are presented as the fold change in gene
expression in the presence of NaHCO3 exposures compared to CA-MHB-Tris alone for each strain, with
CA-MHB-Tris gene expression data being normalized to 1.0.
PBP2a agglutination assays. A semiquantitative, rapid, and reliable latex agglutination method
(Seiken, Tokyo, Japan) was used to measure PBP2a production (72), using beads labeled with specific
anti-PBP2a antibody (73). Strains were grown overnight in specified media (CA-MHB-Tris  44 mM
NaHCO3) at 37°C. Cells were collected by centrifugation, washed once in PBS, resuspended in PBS to an
optical density at 600 nm (OD600) of 1.0, and pelleted. Pellets were prepped for PBP2a agglutination
according to the manufacturer’s instructions. Agglutination results were scored blindly and separately by
two investigators (S.C.E. and L.L.) and scored as high (), moderate (), low (), or negative (–)
based on the presence or absence of an overt agglutination pattern. S. aureus ATCC 43300 (MRSA; PBP2a
positive) and ATCC 25923 (MSSA; PBP2a negative) were used as positive and negative controls,
respectively, in all assays.
Lipase assays. Lipase production is normally repressed by sarA (33, 74). As a phenotypic readout for
NaHCO3-mediated sarA repression, a spectrophotometric assay measuring the rate of clearance of a
tributyrin emulsion was used to measure lipase activity (75). Strains were grown overnight in specified
media (CA-MHB-Tris 44 mM NaHCO3) at 37°C and then diluted to1 109 CFU/ml in same media and
filter sterilized. A 0.5% (vol/vol) tributyrin solution (Sigma) was prepared in 100 mM Tris (pH 8.0) plus
25 mM CaCl2 and emulsified by sonication for 3 min. The tributyrin emulsion was diluted 1:1 with a 0.8%
(wt/vol) low-gelling-temperature agarose (Sigma), and the suspension was maintained at 50°C. Then,
1 ml of the tributyrin suspension was added to 100 l of each supernatant in a spectrophotometric
cuvette, and the OD450 was measured at time zero and at 1, 2, 3, 4, and 5 min. Lipase activity was
calculated as the rate of clearance normalized to the cell density of each sample. A higher rate of
clearance corresponds to greater lipase activity. The data are presented as the fold change in lipase
activity in the presence of NaHCO3 compared to CA-MHB-Tris alone for each strain, with CA-MHB-Tris
alone lipase activity being normalized to 1.0. As stated above, increases in lipase activity correlate with
repression of the sarA gene “tone” (activity) (33).
Rabbit model of MRSA infective endocarditis. To verify the in vivo translatability of the relationship
between NaHCO3 responsiveness or NaHCO3 nonresponsiveness observed in vitro, a well-characterized
rabbit model of indwelling catheter-induced aortic valve infective endocarditis (IE) was used (59). This
model is ideal for these studies since it represents a combined acute bacteremia and subacute
multitarget organ, high-inoculum infection (66). Rabbits were infected intravenously at 48 h after
catheter placement with 2 105 CFU/animal of the indicated strain; this inoculum represents the 95%
infective dose for inducing IE, as established by extensive pilot experiments for each strain. At 24 h
postinfection, the animals were randomized into either an untreated control group (sacrificed at this time
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point as a therapeutic baseline) or -lactam-treated groups (100 mg/kg cefazolin or oxacillin, adminis-
tered by intramuscular injection, three times daily [t.i.d.] for 4 days). These -lactam treatment strategies
encompass (i) dose regimens used in prior studies of experimental IE (5) and (ii) doses that mimic
human-like pharmacokinetics in experimental IE (29).
To provide a perspective on the extent of -lactam-mediated killing in vivo in experimental IE among
NaHCO3-responsive versus NaHCO3-nonresponsive MRSA, we performed a parallel study using the highly
cefazolin-susceptible MSSA strain, ATCC 25923, treated with the same cefazolin treatment regimen used
above for MRSA IE.
In all studies, at 24 h after the last antibiotic treatment, the animals were sacrificed, and their cardiac
vegetations, kidneys, and spleens were removed and quantitatively cultured on TSA. MRSA counts were
expressed as the mean log10 CFU per gram of tissue ( the standard deviations [SD]). To assess the
potential emergence of high-level resistance to either cefazolin or oxacillin for strains MRSA 11/11 and
MW2 during such -lactam treatments, the three target tissues were parallel plated on the above media,
but containing 64 g/ml of the antibiotic of interest. The limit of detection in target organ cultures in this
model, based on average target tissue weights, is 2 log10 CFU/g.
To determine whether preincubation of NaHCO3-responsive MRSA in media containing NaHCO3 itself
might influence the initial induction and/or early progression phases of experimental IE, MRSA 11/11 was
grown overnight in CA-MHB-Tris with either 25 or 44 mM NaHCO3. Rabbits were then infected intrave-
nously at 48 h after catheter placement with 2 105 CFU/animal with NaHCO3-preexposed cells. At 24 h
postinfection, the rabbits were sacrificed, and the same target tissues described above were removed
and quantitatively cultured on TSA.
Statistics. All statistical comparisons were made using a Kruskal-Wallis single-factor analysis of
variance (ANOVA) test and a pairwise Mann-Whitney U test post hoc comparison. The data are presented,
unless otherwise indicated, as the sample means  the SD. P values of 0.05 were considered
statistically significant.
Study approval. Female New Zealand White rabbits (weighing 2.2 to 2.5 kg) were used in all animal
studies (Irish Farm). The rabbits were maintained in accordance with the American Association for
Accreditation of Laboratory Animal Care criteria. The Institutional Animal Care and Use Committee of the
Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center approved all animal study
protocols.
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